Supernus Pharmaceuticals, Inc. · NASDAQ:SUPN
Supernus Pharmaceuticals — Merger or Acquisition (October 2021)
19 slides from Supernus Pharmaceuticals's merger presentation, Oct 12, 2021
Slide 1: Acquisition of Adamas Pharmaceuticals, Inc. Transaction Overview
© 2021 Supernus Pharmaceuticals, Inc. All Rights Reserved. 1 Acquisition of Adamas Pharmaceuticals, Inc. Transaction Overview October 11, 2021
Slide 2: Safe Harbor Statement
© 2021 Supernus Pharmaceuticals, Inc. All Rights Reserved. Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward - looking statements within the meaning of the federal securities laws. These statements, among other t
Slide 3: Additional Information About the Tender Offer and Where to Find it
© 2021 Supernus Pharmaceuticals, Inc. All Rights Reserved. Additional Information About the Tender Offer and Where to Find it The tender offer for the outstanding common stock of Adamas Pharmaceuticals, Inc. (“Adamas”) has not been commenced. This filing does not constitute a recommendation, an offe
Slide 4: Presenters
© 2021 Supernus Pharmaceuticals, Inc. All Rights Reserved. Jack Khattar President and CEO Timothy Dec Senior Vice President, CFO Bryan Roecklein, Ph.D Senior Vice President, Corporate Development Presenters 4
Slide 5: Overview of Transaction Details
© 2021 Supernus Pharmaceuticals, Inc. All Rights Reserved. 5 Overview of Transaction Details Total consideration of up to $9.10/share Upfront payment of $8.10/share ‒ Approximately $400 million upfront (fully - diluted basis) (1) Commercial milestone payments of up to $1.00/share ‒ $0.50/share payab
Slide 6: Adding Commercial Stage Neurology Assets With Significant Revenue
© 2021 Supernus Pharmaceuticals, Inc. All Rights Reserved. 6 Adding Commercial Stage Neurology Assets With Significant Revenue 2020 Net Sales: $71.2M 1H2021 Net Sales: $37.7M; 16.3% growth All trademarks are the property of their respective owners For the treatment of dyskinesia in patients with Par
Slide 7: Strategic Fit and Rationale
© 2021 Supernus Pharmaceuticals, Inc. All Rights Reserved. 7 Strategic Fit and Rationale This acquisition fits squarely with Supernus’ corporate development strategy of adding commercial and late - stage neurology and psychiatry assets Two marketed products Strong strategic fit Strengthens Leading C
Slide 8: Corporate Development Strategy Reduces the Reliance on Trokendi XR
© 2021 Supernus Pharmaceuticals, Inc. All Rights Reserved. 72% 28% Trokendi XR Other SUPN 48% 19% 20% 13% Trokendi XR Other SUPN USWM ADMS Corporate Development Strategy Reduces the Reliance on Trokendi XR 8 Source: Proforma data based on public filings. H1 21 $209M H1 21 $314M Supernus Without Acqu
Slide 9: Parkinson's Disease (PD) Market
© 2021 Supernus Pharmaceuticals, Inc. All Rights Reserved. Parkinson’s Disease (PD) Market U.S. PD Market is anticipated to grow from $1.5B to $6.2B by 2026 (1) Second most common chronic progressive neurodegenerative disorder, affecting 1 - 2% of individuals 65 years and older (2) Number of U.S. PD
Slide 10: GOCOVRI Addresses Significant Unmet Need of Parkinson's Patients
© 2021 Supernus Pharmaceuticals, Inc. All Rights Reserved. GOVOCRI Addresses Significant Unmet Need of Parkinson’s Patients Unique formulation Proven efficacy Differentiated value 10 (1) Kim H - J, et al., Mov Disord , 2020. (2) Mizuno Y et al., Journal of Neural Transmission, 2018. GOCOVRI potentia
Slide 11: Addressing Patient Needs at Different Stages of Parkinson's Disease
© 2021 Supernus Pharmaceuticals, Inc. All Rights Reserved. Addressing Patient Needs at Different Stages of Parkinson’s Disease 11 Stage 1 Stage 1.5 Stage 2 Stage 2.5 Stage 3 Stage 4 Stage 5 Generic Levodopa Initial Symptoms Monotherapy L - dopa Adjuncts On - demand Therapy Advanced continuous treatm
Slide 12: GOCOVRI Has Significantly Decreased Dyskinesia and OFF Time
© 2021 Supernus Pharmaceuticals, Inc. All Rights Reserved. GOCOVRI Has Significantly Decreased Dyskinesia and OFF Time, Thereby Significantly Increasing Good ON Time 12 (1) Elmer LW, CNS Drugs. 2018 . (2) Data on file. Adamas Pharma LLC, Emeryville, CA. * Pooled results from 2 independent positive,
Slide 13: A Comprehensive Commercial Platform in CNS
© 2021 Supernus Pharmaceuticals, Inc. All Rights Reserved. A Comprehensive Commercial Platform in CNS 13 Strengthens CNS portfolio More diversified revenue base and cash flow stream Adds an additional growth asset Epilepsy Migraine Cervical Dystonia Sialorrhea Parkinson’s ADHD Portfolio of Eight Mar
Slide 14: Diversified CNS Portfolio
© 2021 Supernus Pharmaceuticals, Inc. All Rights Reserved. Diversified CNS Portfolio Qelbree Œ , Oxtellar XR ® , Trokendi XR ® , APOKYN ® , MYOBLOC ® , XADAGO ® , GOCOVRI ® , Osmolex ® ER Innovative Pipeline in CNS Qelbree Œ ADHD (adult) SPN - 830 Parkinson’s Disease MYOBLOC Neurological Disorders S
Slide 15: Q&A
© 2021 Supernus Pharmaceuticals, Inc. All Rights Reserved. Q&A 15
Slide 16: Appendix
© 2021 Supernus Pharmaceuticals, Inc. All Rights Reserved. Appendix 16
Slide 17: GOCOVRI
© 2021 Supernus Pharmaceuticals, Inc. All Rights Reserved. 17 GOCOVRI WHAT IS GOCOVRI? GOCOVRI ® (amantadine) extended release capsules is a prescription medicine used: ‒ for the treatment of dyskinesia (sudden uncontrolled movements) in people with Parkinson’s disease who are treated with levodopa
Slide 18: NAMZARIC
© 2021 Supernus Pharmaceuticals, Inc. All Rights Reserved. NAMZARIC 18 NAMZARIC is a prescription medicine approved to treat moderate to severe Alzheimer’s disease in patients who are taking donepezil hydrochloride 10 mg, the active ingredient in Aricept ® . There is no evidence that NAMZARIC preven
Slide 19: OSMOLEX ER
© 2021 Supernus Pharmaceuticals, Inc. All Rights Reserved. OSMOLEX ER 19 OSMOLEX® ER (amantadine) extended - release tablets is indicated for the treatment of Parkinson’s disease and for the treatment of drug - induced extrapyramidal reactions in adult patients. OSMOLEX ER is contraindicated in pati
Supernus Pharmaceuticals — Merger or Acquisition (October 2021) on 6ix